Results 141 to 150 of about 38,631 (238)

Human‐derived cardiac‐neural microtissues reveal catecholaminergic polymorphic ventricular tachycardia is also a disease of the sympathetic neuron

The Journal of Physiology, EarlyView.
Abstract figure legend Schematic diagram illustrating the proposed pathway in which regulatory defects might occur in sympathetic neurons derived from hiPSC in catecholaminergic polymorphic ventricular tachycardia (CPVT). Specifically, enhanced calcium transients appeared to derive from three sources: enhanced membrane excitability (due to loss of ...
Ni Li, Chenchen Zhang, Mengying Xu, YoonYoung Choi, Davi Sidarta‐Oliveira, Ruirui Dong, Xinyu Hu, Enrique M. Toledo, Cesar A. Prada‐Medina, Finbar Argus, Kun Liu, Mingyu Li, Linna Zhou, Hagan Bayley, Corey Smith, Chris Denning, Ana I. Domingos, Guoliang Hao, Dan Li, David J. Paterson   +19 more
wiley   +1 more source

Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients. [PDF]

Egypt Heart J
Shams KA, Ellahony DM, Halima AF, Elzayat RS.   +3 more
europepmc   +1 more source

An age‐associated decline in the role of the sarcoplasmic reticulum and associated calcium‐handling proteins sets the pace for sinoatrial node function

The Journal of Physiology, EarlyView.
Abstract figure legend Stable, responsive pacemaking in the sinoatrial node is driven by the activity of the funny current (membrane clock), interplay of calcium cycling and release from the sarcoendoplasmic reticulum with depolarising sodium‐calcium exchange current (calcium clock). With increasing age, key proteins associated with calcium cycling are
Sandra A. Jones, Fiona S. Godbeer, Matthew K. Lancaster   +2 more
wiley   +1 more source

Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy? [PDF]

J Urol
Flores JM, Vertosick E, Jenkins LC, Cooper J, Benfante N, Sjoberg D, Vickers AJ, Eastham JA, Laudone VP, Scardino PT, Nelson CJ, Mulhall JP.   +11 more
europepmc   +1 more source

Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology. [PDF]

Clin Immunol, 2020
Dal Moro F, Livi U.
europepmc   +1 more source

The Role of Piezo Ion Channels in Pulmonary Hypertension

Pulmonary Circulation, Volume 16, Issue 3, September 2026.
ABSTRACT Pulmonary hypertension (PH) is a chronic and devastating disease that currently lacks effective therapies, often ultimately requiring lung transplantation. Pulmonary vascular cells are subjected to various mechanical forces, which contribute to cardiovascular remodeling in PH.
Kewei Chen, Lingchen Li, Yajie Huang, Lixia Ye, Yu Wang, Ziming Zhang, Chengcheng Hang, Qiqi Li, Qianyun Cao, Lizhong Du   +9 more
wiley   +1 more source

The Clinical and Economic Burden of Pulmonary Arterial Hypertension in Israel, 2014–2022: A Retrospective Analysis of Healthcare Costs and Utilization

Pulmonary Circulation, Volume 16, Issue 3, September 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare, progressive disease with high morbidity and mortality. Real‐world data from Israel are scarce. This study aimed to estimate the incidence, describe treatment patterns, and quantify healthcare utilization and costs associated with PAH in Israel.
Yaki Saciuk, Carole Mamane, Tal Patalon, Laurie Lévy‐Bachelot, Moshe Hoshen, Sarah Sharman Moser, Inbal Shafran, Mohamed Safwat, Yochai Adir, Ran Numa, Eliad Ben‐dayan, Sivan Gazit, Michael J. Segel   +12 more
wiley   +1 more source

Phosphodiesterase type 5 inhibitors related hearing impairment: a real world study based on the FDA adverse event reporting system. [PDF]

Sci Rep
Zhang X, Xia L, Yang Q, Tang P.
europepmc   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation. [PDF]

J Am Heart Assoc, 2020
Xanthopoulos A, Tryposkiadis K, Triposkiadis F, Fukamachi K, Soltesz EG, Young JB, Wolski K, Blackstone EH, Starling RC.   +8 more
europepmc   +1 more source